AI and machine learning hold the promise to revolutionize the healthcare industry in many ways; however, it remains important that these new innovative discoveries in medicine and science lead to better clinical outcomes. This panel will focus on real opportunities and current innovations that improve clinical outcomes by enhancing decision making, creating new diagnostic tools, and enhancing surgical techniques through the use of algorithms and robotics.

Our panel:

• Anuradhika Anuradhika, System VP, Strategic Partnerships, CommonSpirit Health

• Rob Kraal, VP and GM of Connected Health, Zimmer Biomet

• Rob Lindsey, PhD, Co-founder and Chief Technology Officer, Imagen Technologies

• Jonathan Vigdorchik, MD, CEO/Founder OrthoAI; Orthopaedic Surgeon, Hospital for Special Surgery

• Jordan Harmon, Chief Innovation and Commercialization Officer, Hospital for Special Surgery (moderator)

As macro trends continue to drive the need for value-based care adoption across a spectrum of care models, value-based care (VBC) enablers have become an important mechanism by which independent medical groups and health systems can transition from fee-for-service to value-based contracting via wraparound services and affiliation with the enabler's network. In this session, panelists will explore opportunities for growth, challenges to scaling as a VBC enabler and how they evaluate partnership opportunities with the digital health ecosystem.

Our panel:

• Scott Cleary, President, Hyphen

• Michael Meng, Co-Founder & CEO, Stellar Health

• Michael Kopko, Co-Founder & CEO, Pearl Health

• Brandon Sim, Co-CEO, Apollo Medical Holdings

• Vivek Garg, MD, MBA, Chief Medical Officer & SVP, Primary Care, Humana (moderator)

Partnerships are key to building and scaling successful digital health companies. Yet it's often difficult to overcome intertia to get things done. We will review key strategies for 'getting to yes' and share lessons learned and best practices for closing and maintaining key partnerships.

Our panel:

• Jill Dailey, VP, Aetna Commercial Product, CVS Health

• Randy Klein, CEO, Vesta Healthcare

• Edwidge Thomas, VP of Clinical Solutions, Northwell Holdings

• Ron Fleming, Partner, Head of Emerging Companies, Pillsbury (moderator)

Psychedelics have recently demonstrated robust therapeutic effects in a wide range of psychiatric indications, including PTSD, treatment-resistant depression, OCD and substance-use disorders. Yet, the reality is that most people who suffer from mental health illnesses would not be able to access psychedelics like MDMA or psilocybin (if approved). Featuring clinical, scientific, and business leaders on the front lines of the so-called “psychedelic renaissance," this session will review the significant opportunity, as well as the unique risks and challenges.

Our panel:

• Benjamin Kelmendi, MD, Co-Founder and Co-Director, Yale Center for Psychedelic Research

• Jonathan Sabbagh, Co-founder and CEO, Journey Clinical

• Michael Apkon, MD PhD MBA, President, Sand Street Advisors

• Jamila Hokanson, MD MBA, Clinical Instructor and Associate Research Scientist, Yale School of Medicine (moderator)